Clal Insurance Enterprises Holdings Ltd
CLAL INSURANCE ENTERPRISES HOLDINGS LTD
Number in the register: 520036120

To: Israel Securities Authority www.isa.gov.il | To: Tel Aviv Stock Exchange Ltd www.tase.co.il | T087 (Public) | Filed via MAGNA: 07/05/2026 Reference: 2026-01-042574

Share capital status, grant of rights to purchase shares and the corporation's securities registers and changes thereto
Regulation 31E of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 31(a) of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 31(b1) of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 32 of the Securities Regulations (Periodic and Immediate Reports) 5730 - 1970

Nature of the change: Conversion into shares of BONDS Series 2 and full early redemption of Series A
Explanation: A brief description of the nature of the change must be provided

Reference numbers of previous reports on the subject: ________, ________, ________.

1. The corporation's securities position after the change:

Name and type of security	Security No. on TASE	Quantity in the registered capital	Issued and paid-up capital		Quantity registered in the name of the registration company
			Quantity in last report	Current quantity	
Ordinary share, NIS 1 par value	*224014*	*100,000,000*	*80,797,641*	*80,799,510*	*80,798,499*
Warrant Series A, Plan 06/2023	*1198647*	*0*	*425,957*	*425,957*	*0*
Warrant Series A, Plan 06/2024	*1208552*	*0*	*1,286,805*	*1,286,805*	*0*
Warrant Series A, Plan 06/2025	*1223080*	*0*	*130,000*	*130,000*	*0*
Warrant Series B, Plan 06/2025	*1223098*	*0*	*470,000*	*470,000*	*0*
BONDS Series A	*1193481*	*0*	*549,100,060*	*0*	*0*
BONDS Series B	*1193499*	*0*	*88,603,234.48*	*88,453,234.48*	*88,453,234.48*
BONDS Series C	*1201391*	*0*	*850,000,000*	*850,000,000*	*850,000,000*
BONDS Series D	*1239334*	*0*	*604,813,000*	*604,813,000*	*604,813,000*
Clal Insurance RSU	*1231869*	*0*	*8,810*	*8,810*	*0*

Explanation: All the company's securities must be detailed, including securities not listed for trading.

2. The corporation announces that:

- On the date 07/05/2026
- From date ________ to date ________

A change has occurred in the quantity and in the register of holders of the corporation's securities (including rights to purchase shares) as a result of:

Description of the nature of the change: Conversion into shares of BONDS Series 2 and full early redemption of Series 1. See immediate report dated April 16, 2026 (reference 2026-01-035616)

Explanation: A full description must be provided of all the details of the transaction or action that caused the change in the corporation's securities.

1 Name of the registered holder in respect of whom the change occurred: *Registration Company of the Tel Aviv Stock Exchange Ltd*

Type of identification number: *Number in the Israeli Companies Registrar* Identification number: *515736817*

Nature of the change: Conversion of BONDS ________

Date of change: *27/04/2026* Executed through the TASE Clearing House: *Yes*

Type and name of security in which the change occurred: *BONDS Series B*

Security No. on TASE: *1193499*

Holder's balance in the security in last report: *88,603,234.48*

Holder's balance in this security after the change: *88,453,234.48*

Total number of securities in which there was a decrease/increase: *150,000*

Is this a grant of rights to purchase shares *No*

Total consideration for the securities that were allotted: ________

TASE number of the share which will derive from exercise of the security: ________

Number of shares that will derive from full exercise/conversion of the security: ________

Total exercise premium to be received from full exercise/conversion of the security into shares: ________

Period during which the security may be exercised: ________

From ________ to ________

The allotted securities will be listed for trading: ________

The said allotment of securities is further to ________ published on ________ and its reference number is ________

- ☐ The security was fully redeemed and the consideration was paid in full.
- ☐ The security was fully redeemed, but the consideration was not paid in full.
- ☐ Issued for an ATM program
- ☐ Other.

____

---

2 Name of the registered holder in respect of whom the change occurred: *Registration Company of the Tel Aviv Stock Exchange Ltd*

Type of identification number: *Number in the Israeli Companies Registrar* Identification number: *515736817*

Nature of the change: Conversion of BONDS ________

Date of change: *07/05/2026* Executed through the TASE Clearing House: *Yes*

Type and name of security in which the change occurred: *Ordinary share, NIS 1 par value*

Security No. on TASE: *224014*

Holder's balance in the security in last report: *80,796,630*

Holder's balance in this security after the change: *80,798,499*

Total number of securities in which there was a decrease/increase: *1,869*

Is this a grant of rights to purchase shares *No*

Total consideration for the securities that were allotted: ________

TASE number of the share which will derive from exercise of the security: ________

Number of shares that will derive from full exercise/conversion of the security: _________

Total exercise premium to be received from full exercise/conversion of the security into shares:

____

Period during which the security may be exercised: _________

From _________to _________

The allotted securities will be listed for trading: _________

The said allotment of securities is further to _________published on _________and its reference number is _________

- ☐ The security was fully redeemed and the consideration was paid in full.
- ☐ The security was fully redeemed, but the consideration was not paid in full.
- ☐ Issued for an ATM program
- ☐ Other.

____

3

Name of the registered holder in respect of whom the change occurred: *Registration Company of the Tel Aviv Stock Exchange Ltd*

Type of identification number: *Number in the Israeli Companies Registrar*Identification number: *515736817*

Nature of the change: Redemption _________

Date of change: *07/05/2026*Executed through the TASE Clearing House: *Yes*

Type and name of security in which the change occurred: *BONDS Series A*

Security No. on TASE: *1193481*

Holder's balance in the security in last report: *549,100,060*

Holder's balance in this security after the change: *0*

Total number of securities in which there was a decrease/increase: *549,100,060*

Is this a grant of rights to purchase shares *No*

Total consideration for the securities that were allotted: _________

TASE number of the share which will derive from exercise of the security: _________

Number of shares that will derive from full exercise/conversion of the security: _________

Total exercise premium to be received from full exercise/conversion of the security into shares:

____

Period during which the security may be exercised: _________

From _________to _________

The allotted securities will be listed for trading: _________

The said allotment of securities is further to _________published on _________and its reference number is _________

- ☐ The security was fully redeemed and the consideration was paid in full.
- ☐ The security was fully redeemed, but the consideration was not paid in full.
- ☐ Issued for an ATM program
- ☐ Other.

____

Explanations:

1. If the change affects more than one security, the effect of the change must be detailed in a separate line for each security.

2. Date of change – all changes of the same type, in the same security, executed on one day, shall be summarized in one line. For this purpose – a distinction must be made between changes executed through the TASE Clearing House and changes executed directly in the company's books.
3. The change – for a decrease, the "-" sign must be added.
4. In all quantity fields, the quantity of securities must be entered and not NIS par value.

○ The change was only in the corporation's register of securities holders **(without a change in the quantity of the corporation's securities)** as a result of:

Description of the nature of the change ________

Explanation: A full description must be provided of all the details of the transaction or action that caused the change in the register

1 Name of the registered holder in respect of whom the change occurred: ________

Type of identification number: ________ Identification number: ________

Date of change: ________ Executed through the TASE Clearing House: ________

Type and name of security in which the change occurred:

____

Security No. on TASE: ________

Amount of the change: ________

Holder's balance in this security after the change: ________

3. The main points of the shareholders register as of the report date are as follows:

No.	Name of registered shareholder	Type of identification number	Identification number	Security number on TASE	Type of shares and their par value	Number of shares	Whether holds the shares as trustee
1	________	________	________	________	________	________	________

4. Attached is a file of the shareholders register in accordance with Section 130 of the Companies Law, 5759 - 1999 *Share070526_isa.pdf*

5. Attached is an updated file of the corporation's securities registers, including the register of warrant holders and the register of BONDS holders *Warrant_070526_isa.pdf*

Details of the signatories authorized to sign on behalf of the corporation:

	Name of signatory	Position
1	Adv. Adi Barkan Stern	*Company Secretary* ________

Explanation: According to Regulation 5 of the Securities Regulations (Periodic and Immediate Reports) (5730 – 1970), a report submitted pursuant to these regulations shall be signed by the persons authorized to sign on behalf of the corporation. The staff's position on this matter can be found on the Authority's website: Click here .

The warrant plan is based on a mechanism whereby upon exercise of warrants, shares are allotted to the exercising party only according to the value of the benefit (the difference between the market price and the exercise price (cashless exercise)). The calculation of the number of exercise shares of the warrants as detailed below was made under a theoretical maximum assumption of the exercise of all the warrants into shares of the company at the company share price set as a cap on the value of the benefit (with respect to the 2023 plan, a cap price of NIS 113.58 per share was set; with respect to the 2024 plan, a cap price of NIS 85.75 on average per share was set; and with respect to the 2025 warrant plan, a cap price of NIS 156.80 per share was set). It is further emphasized that the above is only a theoretical assumption, since the exercise shares will actually be allotted in a quantity that will reflect the monetary benefit value that will be embedded in the warrants at the time of exercise and that will be lower. Below are the exercise ratios of the warrants into shares in accordance with the above: Warrant Series A, Plan 06/2023 0.487 Warrant Series A, Plan 06/2024 0.250 Warrant Series A and B, Plan 06/2025 0.375

Reference numbers of previous documents on the subject (the reference does not constitute inclusion by way of reference):

The corporation's securities are listed for trading on the Tel Aviv Stock Exchange

Date of form structure update: 06/08/2024

Short name: Clal Insurance Enterprises

Address: Raoul Wallenberg36 , Tel Aviv, P.O.B. 370706136902 Telephone: 03-6387575 , 03-6387577Fax: 03-6397011

Email: ClalMishpatit@clal-ins.co.il

Previous names of reporting entity:

Name of electronic reporter: Barkan Stern AdiPosition: Company SecretaryName of employing company: Clal Insurance Company Ltd

Address: Raoul Wallenberg36 , Tel Aviv P.O.B. 370706136902Telephone: 077-6387634Fax: 03-7965879Email: AdiBark@clal-ins.co.il